Matches in Wikidata for { <http://www.wikidata.org/entity/Q37148350> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- Q37148350 description "article científic" @default.
- Q37148350 description "article scientifique" @default.
- Q37148350 description "articolo scientifico" @default.
- Q37148350 description "artigo científico" @default.
- Q37148350 description "artículu científicu espublizáu en 2008" @default.
- Q37148350 description "bilimsel makale" @default.
- Q37148350 description "bài báo khoa học" @default.
- Q37148350 description "scientific article published on 26 April 2008" @default.
- Q37148350 description "vedecký článok" @default.
- Q37148350 description "vetenskaplig artikel" @default.
- Q37148350 description "videnskabelig artikel" @default.
- Q37148350 description "vědecký článek" @default.
- Q37148350 description "wetenschappelijk artikel" @default.
- Q37148350 description "wissenschaftlicher Artikel" @default.
- Q37148350 description "наукова стаття, опублікована у квітні 2008" @default.
- Q37148350 description "научни чланак" @default.
- Q37148350 description "مقالة علمية نشرت في 26 أبريل 2008" @default.
- Q37148350 name "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 name "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 name "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 type Item @default.
- Q37148350 label "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 label "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 label "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 prefLabel "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 prefLabel "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 prefLabel "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 P1433 Q37148350-FBBA357F-5529-4A60-A571-80B6CD8BB264 @default.
- Q37148350 P1476 Q37148350-11CDBF79-28B7-45FE-8C4C-07696B7282C0 @default.
- Q37148350 P2093 Q37148350-5F23BC46-2D6F-4A6A-84D4-93C4AADE880D @default.
- Q37148350 P2093 Q37148350-A72ECFDC-48EF-4F1A-BADD-E14AD7EF66AA @default.
- Q37148350 P2093 Q37148350-E24AA8A0-A208-452E-B17D-55981ED7D90E @default.
- Q37148350 P2093 Q37148350-F53E7FAD-CCDA-4F52-B0DE-19C343BB657B @default.
- Q37148350 P2860 Q37148350-059CA51F-D3BC-4859-AE4F-496A61F0F552 @default.
- Q37148350 P2860 Q37148350-05CCF107-81ED-4A07-AF16-3D79FE25FD1E @default.
- Q37148350 P2860 Q37148350-0EC8B1BF-4C59-473F-ABB1-9789D09A69FD @default.
- Q37148350 P2860 Q37148350-188ED555-E41D-41EF-80D0-6F2765DE5320 @default.
- Q37148350 P2860 Q37148350-1964C0D6-D315-4C48-B5CD-33F346A1B726 @default.
- Q37148350 P2860 Q37148350-1BE1DA8E-B7D6-4BA0-9C2B-A88E03167BE6 @default.
- Q37148350 P2860 Q37148350-31A4A004-BF3D-47BE-8D2D-73861CBB54ED @default.
- Q37148350 P2860 Q37148350-750E3FFB-18E5-4621-82F2-A180B30FC211 @default.
- Q37148350 P2860 Q37148350-75C57788-5CDE-4409-905C-2E613E8B197C @default.
- Q37148350 P2860 Q37148350-7D49745B-9CCC-4B8E-AEA9-6C02B309C79D @default.
- Q37148350 P2860 Q37148350-8FEC36C1-4B6F-4845-A0EB-2231FD6E9ECD @default.
- Q37148350 P2860 Q37148350-B29020F7-E1AD-4301-8CAC-DC89D2F5FE2A @default.
- Q37148350 P2860 Q37148350-C0CF674A-CB22-47B4-9BD6-1D3AD0F86A32 @default.
- Q37148350 P2888 Q37148350-EC0351A0-0EAB-4441-86B7-EA00ECAA859B @default.
- Q37148350 P304 Q37148350-B7D19860-46FE-4F33-9318-7724739A65D4 @default.
- Q37148350 P31 Q37148350-7CCE9E47-3840-4AEB-B91E-79311460D818 @default.
- Q37148350 P356 Q37148350-5F1F4DF3-A75E-4561-A70C-299145D1A027 @default.
- Q37148350 P433 Q37148350-493F936F-B4C8-4772-9ABB-5A0BBD361231 @default.
- Q37148350 P478 Q37148350-DFF72707-15EA-4E27-A346-0403A78D60E3 @default.
- Q37148350 P577 Q37148350-5BF1B53F-EFE0-419D-8A1E-8BC1699EB325 @default.
- Q37148350 P698 Q37148350-C7C0B819-A7A7-4F76-BD90-BC7BF2BBEE88 @default.
- Q37148350 P921 Q37148350-2C8E6FA8-A85C-478D-BE94-1474D1D10FED @default.
- Q37148350 P921 Q37148350-33DBA007-8C3E-4CBC-B796-776EE9CFF2DE @default.
- Q37148350 P921 Q37148350-6D12177A-00B9-4DAC-9FE9-E52CF6B3050E @default.
- Q37148350 P356 S11060-008-9599-0 @default.
- Q37148350 P698 18438609 @default.
- Q37148350 P1433 Q15752119 @default.
- Q37148350 P1476 "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" @default.
- Q37148350 P2093 "David Peereboom" @default.
- Q37148350 P2093 "Heinrich Elinzano" @default.
- Q37148350 P2093 "Tony Jin" @default.
- Q37148350 P2093 "Tyler Y Kang" @default.
- Q37148350 P2860 Q27860910 @default.
- Q37148350 P2860 Q30444953 @default.
- Q37148350 P2860 Q33453675 @default.
- Q37148350 P2860 Q34599824 @default.
- Q37148350 P2860 Q35895167 @default.
- Q37148350 P2860 Q40789890 @default.
- Q37148350 P2860 Q46942082 @default.
- Q37148350 P2860 Q48207492 @default.
- Q37148350 P2860 Q48264845 @default.
- Q37148350 P2860 Q48821565 @default.
- Q37148350 P2860 Q55473747 @default.
- Q37148350 P2860 Q55485939 @default.
- Q37148350 P2860 Q63988512 @default.
- Q37148350 P2888 s11060-008-9599-0 @default.
- Q37148350 P304 "113-118" @default.
- Q37148350 P31 Q13442814 @default.
- Q37148350 P356 "10.1007/S11060-008-9599-0" @default.
- Q37148350 P433 "1" @default.
- Q37148350 P478 "89" @default.
- Q37148350 P577 "2008-04-26T00:00:00Z" @default.
- Q37148350 P698 "18438609" @default.
- Q37148350 P921 Q233309 @default.
- Q37148350 P921 Q412197 @default.
- Q37148350 P921 Q413299 @default.